Home HOME Acta Virologica 2020 Acta Virologica Vol.64, No.4, p.389-395, 2020

Journal info


Quarterly,
Founded: 1957
ISSN 0001-723X
E-ISSN 1336-2305

Published in English

Aims and Scope
Editorial Info

Abstracted and Indexed
Submission Guidelines

Select Journal







Webshop Cart

Your Cart is currently empty.

Info: Your browser does not accept cookies. To put products into your cart and purchase them you need to enable cookies.

Acta Virologica Vol.64, No.4, p.389-395, 2020

Title: Immunotherapy approaches on innate immunity for SARS-Cov-2
Author: B. A. Arslan, A. C. Timucin

Abstract: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused fatal outbreaks of pneumonia. The similarity of S protein of SARS-CoV-2 with SARS-CoV and RaTG13 is about 76% and 97%, respectively. Also its potential receptor-binding domain (RBD) shows similarity with approximately 74% and 90.1% for SARS-CoV and RaTG13, respectively. SARS-CoV-2 has been shown to use the SARS-CoV receptor ACE2 for entry and serine protease TMPRSS2 for S protein priming. Sialic acids are primarily expressed by vertebrates and some microbial pathogens improving the ability to avoid immune system of vertebrate host. Interactions of sialic acid-binding Ig-like lectins (Siglecs) with their ligands play an important role in modulating immune cell function activities as their regulators. Therefore, while Siglecs help immune cells to distinguish between self and non-self, non-self ligands of some sialylated pathogens can recognize Siglecs and reduce immune cell responses or escape from immune surveillance. In this review, innate immunity in SARS-Cov-2 infection was discussed through Siglecs, especially Siglec-7, Siglec-3, NKG2A and neuraminidases.

Keywords: SARS-Cov-2; siglecs; NK cells; NKG2A; neuraminidases
Published online: 03-Jul-2020
Year: 2020, Volume: 64, Issue: 4 Page From: 389, Page To: 395
doi:10.4149/av_2020_401


download file



© AEPress s.r.o
Copyright notice: For any permission to reproduce, archive or otherwise use the documents in the ELiS, please contact AEP.